By Josh White
Date: Wednesday 03 Sep 2025
(Sharecast News) - Shield Therapeutics reported a sharp rise in first-half revenue on Wednesday, as sales of its oral iron therapy Accrufer accelerated across key markets, leaving the company on track to reach cash flow breakeven by the end of 2025.
For the six months ended 30 June, revenue jumped 1.8...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news